FDA approves AstraZeneca's Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma

AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Calquence (acalabrutinib). Calquence is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news